Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Wilhelm

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Hematological Oncology|July 13, 2016
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphomaBarbara Pro, Steven M Horwitz, H Miles Prince, et al.
Clinical Colorectal Cancer|June 4, 2016
Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical PracticeMartin Wilhelm, Lothar Mueller, M Craig Miller, et al.
Interventional Neuroradiology : Journal of Peritherapeutic Neuroradiology, Surgical Procedures and Related Neurosciences|September 6, 2023
Virtual reality simulation training in stroke thrombectomy centers with limited patient volume-Simulator performance and patient outcomeOlav Søvik, Arnstein Tveiten, Halvor Øygarden, et al.
Journal of Hematology & Oncology|January 25, 2014
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Haematologica|May 9, 2020
Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II studyFranck Morschhauser, Kamal Bouabdallah, Stephan Stilgenbauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2009
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 studyAndreas Engert, Volker Diehl, Jeremy Franklin, et al.
Polymers|January 1, 2020
Hydrofilm Polyurethane Films Reduce Radiation Dermatitis Severity in Hypofractionated Whole-Breast Irradiation: An Objective, Intra-Patient Randomized Dual-Center AssessmentLeonard Christopher Schmeel, David Koch, Frederic Carsten Schmeel, et al.
Lancet (London, England)|August 11, 2012
Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised studyHannes Wandt, Kerstin Schaefer-Eckart, Knut Wendelin, et al.
Cancer Investigation|September 20, 2006
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphomaUlrich J M Mey, Katjana S Orlopp, Dimitri Flieger, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Hematological Oncology|July 13, 2016
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphomaBarbara Pro, Steven M Horwitz, H Miles Prince, et al.
Clinical Colorectal Cancer|June 4, 2016
Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical PracticeMartin Wilhelm, Lothar Mueller, M Craig Miller, et al.
Interventional Neuroradiology : Journal of Peritherapeutic Neuroradiology, Surgical Procedures and Related Neurosciences|September 6, 2023
Virtual reality simulation training in stroke thrombectomy centers with limited patient volume-Simulator performance and patient outcomeOlav Søvik, Arnstein Tveiten, Halvor Øygarden, et al.
Journal of Hematology & Oncology|January 25, 2014
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Haematologica|May 9, 2020
Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II studyFranck Morschhauser, Kamal Bouabdallah, Stephan Stilgenbauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2009
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 studyAndreas Engert, Volker Diehl, Jeremy Franklin, et al.
Polymers|January 1, 2020
Hydrofilm Polyurethane Films Reduce Radiation Dermatitis Severity in Hypofractionated Whole-Breast Irradiation: An Objective, Intra-Patient Randomized Dual-Center AssessmentLeonard Christopher Schmeel, David Koch, Frederic Carsten Schmeel, et al.
Lancet (London, England)|August 11, 2012
Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised studyHannes Wandt, Kerstin Schaefer-Eckart, Knut Wendelin, et al.
Cancer Investigation|September 20, 2006
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphomaUlrich J M Mey, Katjana S Orlopp, Dimitri Flieger, et al.
Pageof 10